Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: A prospective randomized single-center pilot study

Transplantation

Volumn 81, Issue 7, 2006, Pages 1010-1015

  Kyllönen, Lauri E ^a   Salmela, Kaija T ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

C0; C2; Cyclosporine monitoring; Immunosuppression; Kidney transplantation

Indexed keywords

CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ADULT; AGED; ARTICLE; CADAVER KIDNEY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIARRHEA; DRUG BLOOD LEVEL; DRUG MONITORING; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART DISEASE; HEARTBURN; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSOMNIA; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL NEUROPATHY; PILOT STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SURVIVAL RATE; TREMOR; UNSPECIFIED SIDE EFFECT; UREMIA; VERTIGO; VOMITING;

ADULT; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 33646356239     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000203306.72858.df     Document Type: Article

References (22)

1. Pescovitz MD, Barbeito R. Simulect US01 Study Group. Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts. Clin Transplant 2002; 16: 378-382.
2. 2 monitoring: an international consensus. Transplantation 2002; 73(9): S12-S18.
3. International Neoral Renal Transplantation Study Group: Randomized, international study of Cyclosporine Microemulsion absorption profiling in renal transplantation with Basiliximab immunosuppression. Am J Transpl 2002; 2: 157-166.
4. Lindholm A, Kahan B. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205-218.
5. Cantarovich M, Besner J-G, Barkun J, et al. Two-hour cyclosporine level determination is he appropriate tool to monitor Neoral therapy. Clin Transpl 1998; 12: 243-249.
6. Cole E, Maham N, Cardella C, et al. Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients. Transplantation 2003; 75: 2086-2090.
7. Pfeffer P, Stefoni S, Carreno C, et al. Monitoring of 2-hour Neoral® absorption in renal transplantation shows low incidence of acute rejection in the early post-graft period: Interim results of the MO2ART study. Abstract 1037, ATC, 2002, Washington DC.
8. Salmela K, Kyllönen L. Two decades of experience with cyclosporine in renal transplantation in Helsinki. Transplant Proc 2004; 36(2 Suppl): 94S-98S.
9. Belitsky P, Levy GA, Johnston A. Neoral absorption profiling: An evolution in effectiveness. Transplant Proc 2000; 32(3A Suppl): 45S-52S.
10. 2 monitoring in clinical practice. Transplantation 2002; 73(9): S19-S22.
11. Halloran PF, Aprile MA, Farewell V, et al. Early function as the principal correlate of graft survival. A multivariate analysis of 200 cadaveric renal transplants treated with a protocol incorporating antilymphocyte globulin and cyclosporine. Transplantation 1988; 46: 223-228.
12. Salmela K, Kyllonen L. Early cyclosporine concentration as predictor of graft survival in cadaveric renal transplantation. Transplant Proc 2001; 33: 2441-2443.
13. Perico N, Ruggeneti P, Gotti E, et al. In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: Insights from the M.Y.S.S. trial. Kidney Int 2004; 65: 1084-1090.
14. Solez K, Vicenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66(12): 1736-1740.
15. Ortiz F, Paavonen T, Törnroth T, et al. Predictors of renal allograft histologic damage progression. J Am Soc Nephrol, in press
16. Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve; its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68: 55-62.
17. Canadian Neoral renal transplantation study group. Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation 2001; 72: 1024-1032.
18. Kelles A, Herman J, Tjandra-Maga TB, Van Damme-Lombaerts R. Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients. Pediatr Transplant 1999; 3: 282-287.
19. Stefoni S, Midtved K, Cole E, et al. Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of Cyclosporine A microemulsion: Results of a 12-month, randomized, multicenter study. Transplantation 2005; 79: 577-583.
20. Clase CM, Mahalati K, Kiberd BA, et al. Adequate early cyclosporine exposure is critical to prevent renal allograft rejection: Patients monitored by absorption profiling. Am J Transplantation 2002; 2: 789-795.
21. Birsan T, Loinig C, Bodingbauer M, et al. Comparison between C0 and C2 monitoring in de novo renal transplant recipients: Retrospective analysis of a single center experience. Transplantation 2004; 78: 1787-1791.
22. Hardinger K, Schnitzler M, Koch M, et al. Cyclosporine minimization and cost reduction in renal transplant recipients receiving a C2-monitored, cyclosporine-based quadruple immunosuppressive regimen. Transplantation 2004; 78: 1198-1203.